Publications may either be freely available or require a fee to view (or access) on the journal’s website.
People with cardiovascular disease who took aspirin to lower their chances of having a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization, whether they took a high or low dose of the medication, according to findings from the PCORI-funded ADAPTABLE Study, the largest aspirin dosing trial conducted in routine care and clinical settings. The results were presented at ACC.21 – the American College of Cardiology’s 70th Annual Scientific Session – and simultaneously published in the New England Journal of Medicine in May 2021.
The study is also the first randomized controlled trial conducted using PCORnet®, the National Patient-Centered Clinical Research Network. Learn more about the findings here, at TheAspirinStudy,org, or through these English or Spanish results summaries.